The nine-count federal indictment alleges that Michael McMillan used reimbursement-linked payments to influence medical providers, generate false wound-care claims, reward sales representatives, and purchase valuable property with money prosecutors characterize as criminally derived proceeds.
WASHINGTON, DC — Michael McMillan faces federal charges including healthcare fraud, kickbacks, and money laundering allegations arising from an extensive wound-care prosecution that places provider incentives, reimbursement disclosures, and multimillion-dollar property transactions under scrutiny.
Federal prosecutors accuse the fifty-five-year-old Las Vegas businessman of controlling several Protectus companies that allegedly supplied skin-substitute products through arrangements designed to reward medical providers whenever Medicare or other government programs reimbursed their claims.
The indictment contains nine counts, covering an alleged conspiracy to commit healthcare fraud, a separate conspiracy involving federal-program kickbacks, and seven transactions prosecutors say used more than $10,000 in property derived from the underlying charged conduct.
McMillan remains presumed innocent; every accusation requires proof in court, and neither the size of the alleged reimbursement stream nor the value of seized property establishes that he knowingly committed any charged offense.
The prosecution therefore presents a layered legal case rather than a single, undifferentiated fraud claim, because each conspiracy requires proof of its own agreement and purpose, while every alleged proceeds transaction must satisfy additional financial elements.
A Nine-Count Indictment with Three Legal Components
Count One charges McMillan with conspiracy to commit healthcare fraud under Title 18, Section 1349, based upon an alleged agreement to cause materially false or kickback-induced claims for skin-substitute products to reach government benefit programs.
Count Two charges a conspiracy under Title 18, Section 371 to defraud the United States and offer or pay remuneration intended to induce purchases, orders, recommendations, or arrangements involving federally reimbursable healthcare goods and services.
Counts Three through Nine invoke Title 18, Section 1957, alleging that McMillan knowingly engaged in seven monetary transactions exceeding $10,000 using property derived from the healthcare-fraud and kickback conspiracies identified as specified unlawful activity.
Although news coverage often summarizes those final counts as money laundering, their formal language concerns monetary transactions in criminally derived property, a distinction that becomes important when evaluating what prosecutors must prove and what they need not prove.
The Healthcare Fraud Conspiracy Allegation
The government alleges that McMillan participated in the healthcare-fraud conspiracy from approximately May 2019 through at least February 2026, operating in the Northern District of Texas and elsewhere through companies he allegedly owned and controlled.
Those companies include Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC, which the indictment collectively identifies under the Protectus name.
Prosecutors say the conspiracy sought to enrich McMillan and unnamed participants by causing claims containing material misrepresentations and claims allegedly induced through illegal remuneration to be submitted for payment by federal healthcare benefit programs.
The charged theory does not depend solely upon whether a physical skin-substitute product existed, because a genuine product applied to an actual patient can still generate an ineligible claim when material billing information is false, or remuneration corrupts the transaction.
Conversely, a large payment or unusually expensive product cannot establish criminal fraud alone, because prosecutors must prove a knowing agreement, material deception, and the required link between the challenged representations and program payments.
How the Alleged Provider Arrangement Worked
According to the indictment, Protectus offered skin-substitute products to physicians, podiatrists, nurse practitioners, and other providers without demanding upfront payment, allowing participating practices to wait until government reimbursement decisions arrived before paying for the products.
When Medicare, TRICARE, or CHAMPVA allegedly reimbursed a claim, Protectus charged the provider approximately sixty percent to seventy percent of the reimbursement, leaving the practice with approximately thirty percent to forty percent as an assured financial margin.
When a claim was denied, prosecutors say Protectus did not charge the medical provider for the supplied product, an arrangement that allegedly removed significant acquisition risk while preserving substantial rewards whenever a government payer approved reimbursement.
The government characterizes the retained provider share as an illegal kickback disguised through rebate, discount, or profit language, alleging that the economic arrangement encouraged clinicians to choose and bill products supplied through McMillan’s companies.
McMillan may dispute that characterization by arguing that providers independently selected clinically appropriate products, the contracts allocated legitimate collection risk, percentage pricing reflected commercial realities, and applicable discount rules permitted the disclosed economic terms.
Why Medical Decisions Sit at the Center of the Case
Federal anti-kickback law addresses remuneration offered to induce purchasing, ordering, arranging, or recommending federally reimbursable items, meaning prosecutors need not reduce the alleged influence to a direct payment expressly labeled as compensation for treating one named patient.
The indictment instead describes a standing economic incentive under which greater reimbursed product use allegedly generated greater provider margins, allowing prosecutors to argue that financial rewards were embedded within repeated clinical and purchasing decisions across several practices.
Medical providers nevertheless retain independent professional obligations, and the government must prove McMillan knowingly joined the charged agreement rather than assuming his intent from the fact that customer practices earned money after successful reimbursement.
Clinical records may show whether products were medically necessary and properly applied, but Count One also focuses on price representations and kickback-tainted claims, so medical necessity alone cannot resolve every alleged route to ineligibility.
Careful reporting should therefore avoid claiming that every wound treatment was unnecessary, every provider acted corruptly, or every patient received improper care, because the public charging document presents broader financial allegations without adjudicating each individual claim.
The Alleged Price Misrepresentation
The indictment says medical providers were required to disclose their actual skin-substitute acquisition price, including discounts, rebates, refunds, and other adjustments, through the claim information prosecutors identify as Box 19 on Medicare submissions.
Prosecutors allege McMillan and Protectus submitted, assisted with, or advised the submission of inflated prices that did not reflect what practices truly paid after the contingent invoice terms and reimbursement-based adjustments were considered.
That allegation supplies the fraud theory with a representation capable of documentary testing, because contracts, invoices, credits, refunds, claim forms, payment records, and correspondence can be compared to reconstruct each provider’s complete economic obligation.
The defense can challenge whether the government selected the correct pricing rule, interpreted contingent obligations accurately, accounted for product and collection risks, or proved that McMillan understood any disputed entry was false when the corresponding claim was submitted.
An administrative disagreement, ambiguous instruction, or isolated billing mistake does not automatically become criminal healthcare fraud, but repeated internal directions, reimbursement-linked corrections, or concealed adjustments could support intent when considered with corroborating evidence.
Medicare, TRICARE, and CHAMPVA Payments
The alleged claims reached Medicare, the military’s TRICARE system, and the Department of Veterans Affairs program known as CHAMPVA, extending the prosecution across healthcare programs serving older adults, disabled beneficiaries, military families, and qualifying veterans’ relatives.
The Northern District of Texas Justice Department announcement says approximately $268 million in false or fraudulent wound-product claims were submitted and paid, while McMillan and Protectus allegedly received approximately $174 million from that reimbursement stream.
The indictment describes approximately $94 million as provider kickbacks, which corresponds to the portion allegedly retained by practices rather than an additional government payment that should be added to the approximately $268 million total.
Those figures describe the government’s current allegations, not an adjudicated program-loss calculation, final restitution amount, personal-income finding, or judicial determination that every included claim was false for the same reason across the charged period.
Claim-level evidence will matter because product selection, wound condition, reimbursement instructions, invoicing, provider knowledge, payer rules, and disclosures may vary considerably across patients, practices, dates, programs, and skin-substitute products under the charged arrangements.
Count Two Focuses on Kickbacks and Government Functions
Count Two alleges that McMillan conspired both to obstruct lawful federal administration through dishonest means and to offer or pay remuneration intended to induce orders or recommendations involving items reimbursable under a federal healthcare program.
Unlike Count One’s healthcare-fraud conspiracy statute, the general conspiracy provision charged in Count Two requires prosecutors to establish an agreement, unlawful purpose, knowing participation, and an overt act committed to advance the alleged arrangement.
The indictment identifies numerous alleged overt acts involving invoices, commission reports, reimbursement notices, emails, checks, meetings, claim instructions, refunds, and provider communications occurring between October 2022 and May 2024 across several participating relationships.
Those entries seek to transform the prosecution’s broad theory into a chronology showing that provider invoices and representative compensation allegedly moved in response to insurance reimbursement rather than through fixed product prices established independently beforehand.
McMillan can challenge the meaning, completeness, authorship, and context of every selected record, while prosecutors may argue that repeated consistency across unrelated providers and representatives demonstrates a common system rather than isolated commercial improvisation.
Sales Representatives Add a Second Alleged Payment Layer
Prosecutors allege McMillan hired sales representatives to recruit medical providers, explain the profit-sharing arrangement, and receive compensation calculated from amounts Protectus collected after government programs reimbursed claims generated by the practices they recruited.
The indictment says Protectus paid approximately $27 million in allegedly illegal compensation to sales representatives, an amount that appears downstream from Protectus receipts and should not be counted as another separate category of federal reimbursement.
Sales commissions are not inherently unlawful merely because performance affects compensation, but healthcare arrangements create heightened exposure when payments allegedly reward referrals, recommendations, or federally reimbursable orders through relationships that can influence clinical behavior.
Investigators can compare representative agreements with payment reports, customer recruitment records, claim histories, invoices, bank transfers, emails, and messages to determine whether written sales descriptions matched how compensation operated in practice throughout the alleged scheme.
The defense may argue that representatives performed legitimate product education and account services, compensation reflected lawful sales activity, and no payment induced an improper medical decision, leaving the government to prove unlawful intent beyond correlation.
Overt Acts Illustrate the Government’s Theory
One indictment example describes a provider invoice reflecting approximately $53,625 in collected reimbursement, approximately $16,087 retained by the practice, and approximately $37,537 due to a Protectus company after the government payment arrived.
Another example alleges that a provider questioned why an invoice reflected a thirty-five-percent margin instead of a forty-percent contractual margin, after which McMillan forwarded the communication internally and requested that the document be corrected.
A separate provider allegedly reported one reimbursed claim and one denied claim, later receiving an invoice for $5,865.60, which represented sixty-five percent of the $9,024 payment reported to Protectus for the successful submission.
The indictment also describes commission communications allegedly linking representative payments to reimbursements collected by their recruited medical providers, evidence prosecutors may use to argue that both commercial layers depended directly on federal claim outcomes.
Each episode remains an allegation drawn from the government’s selected evidence, and complete discovery may supply surrounding communications, contract provisions, accounting explanations, or witness testimony that changes how jurors understand the summarized exchange.
Seven Alleged Criminal-Proceeds Transactions
Counts Three through Nine charge violations of Section 1957, which generally prohibits knowingly conducting qualifying monetary transactions exceeding $10,000 in property derived from specified unlawful activity under defined United States jurisdictional circumstances.
The alleged specified unlawful activities are the conspiracies charged in Counts One and Two, meaning prosecutors must first prove an unlawful proceeds source before establishing that a later purchase involved criminally derived property.
The seven counts identify transactions connected with four residences, two luxury vehicles, and a private aircraft, with dates extending from December 2021 through September 2025 and specified amounts totaling approximately $6.28 million.
Each count stands separately, requiring evidence about its originating account, timing, amount, financial institution, property, source of funds, and McMillan’s knowledge rather than allowing one successful tracing theory to decide every transaction automatically.
The government does not need to prove that McMillan knew the precise statutory identity of the underlying specified unlawful activity, but it must establish the knowledge concerning criminal derivation required by Section 1957.
Homes, Vehicles, and an Aircraft Form the Transaction Schedule
Count Three alleges an approximately $1.01 million transaction involving a Dallas condominium, while Count Four identifies a $60,000 transaction from a Protectus account associated with a 2023 Lamborghini Urus Performance during the charged period.
Count Five concerns approximately $260,466 connected with a Las Vegas residence, and Count Six alleges a $1.3 million transaction from a McMillan account involving residential property located in Simpsonville, Kentucky during the following year.
Count Seven identifies approximately $1.04 million associated with real estate in Del Mar, California, while Count Eight concerns a $50,000 Protectus transaction associated with a 2023 Cadillac Escalade through a specified company account.
Count Nine alleges an approximately $2.56 million payment from an Elite Elevated Enterprises account involving a 1997 Cessna Citation VII, making the private-aircraft transaction the largest monetary count specified in the indictment.
The amounts listed for vehicle transactions may reflect specific charged payments rather than full purchase prices, current equity, or market values, underscoring why the schedule cannot serve as a comprehensive valuation of every targeted asset.
Why Transactional Money Laundering Is the Precise Description
Section 1957 is commonly described as a transactional or spending money-laundering statute because it reaches qualifying uses of criminally derived property, even when prosecutors do not allege that concealment itself was the transaction’s purpose.
The McMillan indictment does not charge the better-known concealment, promotion, international-transfer, or reporting-evasion theories associated with Section 1956, making it inaccurate to suggest that every alleged purchase involved a separate plan to hide money.
Instead, the prosecution alleges that money derived from healthcare fraud and kickback conspiracies moved through financial transactions exceeding the statutory threshold to acquire identifiable property, including real estate, vehicles, and an aircraft described throughout the indictment.
That distinction still carries substantial criminal exposure, because Section 1957 authorizes imprisonment of as much as ten years for each violation, although statutory maximums are ceilings rather than predictions about any eventual sentence.
The conspiracy charged in Count One generally carries the penalties applicable to the underlying healthcare-fraud offense, while the Section 371 conspiracy in Count Two generally carries a maximum five-year term of imprisonment under ordinary circumstances.
The Financial Totals Must Remain Separate
The approximately $268 million paid on challenged claims represents alleged program reimbursement, while approximately $174 million describes alleged Protectus receipts and approximately $94 million describes the provider share prosecutors characterize as kickbacks within the alleged distribution model.
The approximately $27 million allegedly paid to representatives came from the distribution side of the reimbursement stream, preventing responsible reporting from adding that amount to program payments as though federal agencies issued unrelated additional money.
The approximately $6.28 million specified across seven monetary counts represents selected property transactions, not the full alleged proceeds, a final loss calculation, or the total value of assets investigators restrained during the ongoing investigation.
Authorities separately reported approximately $35 million in assets seized in connection with McMillan’s case, a provisional enforcement figure that does not establish final ownership, net equity, criminal traceability, or permanent forfeiture at the announcement stage.
Keeping every amount within its correct category prevents submitted claims, paid claims, company revenue, provider margins, representative commissions, personal income, seized property, restitution, loss, and forfeiture from collapsing into one misleading number across the public narrative.
Seizure and Forfeiture Are Not Conviction
Federal seizure can preserve property during litigation, preventing sale, transfer, dissipation, or removal while courts determine whether the government possesses a legally sufficient basis for permanent criminal forfeiture after conviction through authorized judicial procedures.
The indictment seeks proceeds traceable to the charged conspiracies, property involved in or traceable to the Section 1957 transactions, a money judgment based upon alleged gross proceeds, and potentially substitute property under defined statutory circumstances.
Its forfeiture notice identifies residential property in Dallas, Del Mar, Simpsonville, and two Las Vegas locations, but the government’s public announcement does not provide a complete itemized inventory reconciling every seized asset with its approximately $35 million estimate.
Mortgages, liens, co-ownership, financing, depreciation, appraisals, legitimate deposits, and third-party interests can materially affect recoverable value, even when prosecutors establish that some portion of an asset was acquired with unlawful proceeds during any ancillary proceeding.
Images of luxury cars, expensive residences, and private aviation can make an abstract reimbursement case memorable, but wealth itself cannot substitute for evidence proving criminal source, knowledge, agreement, falsity, and traceability for the particular defendant.
What Prosecutors Must Prove at Trial
For Count One, prosecutors must establish that the healthcare-fraud agreement existed, McMillan knowingly and willfully joined it, and its intended execution involved materially false pretenses or representations connected with government payment for healthcare items or services.
For Count Two, they must prove the charged agreement, McMillan’s knowing participation, its objective of defrauding federal functions or paying prohibited remuneration, and at least one overt act committed to advance the conspiracy.
For each Section 1957 count, the government must establish a qualifying monetary transaction exceeding $10,000, criminally derived property from specified unlawful activity, the required financial-institution and jurisdictional connection, and McMillan’s legally sufficient knowledge.
Evidence may include provider testimony, representative communications, claim data, invoices, bank records, product shipments, contracts, reimbursement notices, commission reports, accounting books, property documents, and expert explanations concerning federal billing requirements throughout the charged period.
The strongest prosecution presentation would connect those evidence categories chronologically, showing how product placement allegedly produced claims, how reimbursements allegedly determined invoices and commissions, and how resulting receipts allegedly funded the specific acquisitions charged.
Questions Available to McMillan’s Defense
Defense counsel can challenge whether providers exercised independent medical judgment, whether products delivered genuine clinical value, whether pricing disclosures followed reasonable guidance, and whether rebates or contingent terms fit lawful commercial and regulatory frameworks.
Attorneys may scrutinize claim sampling, provider credibility, communications selected from a nearly seven-year period, expert assumptions, billing consultants, safe-harbor analysis, corporate boundaries, and the government’s treatment of legitimate product expenses or operating costs.
For the financial counts, the defense can trace lawful revenue, loans, savings, financing, unrelated deposits, owner contributions, and commingled balances while contesting whether more than $10,000 in criminally derived property entered each selected transaction.
McMillan may also challenge searches, seizures, venue, admissibility, ownership, valuation, causation, materiality, and forfeiture scope, although the availability of those arguments does not mean any court has accepted them or rejected the prosecution.
The defense does not need to prove an alternative narrative to secure acquittal, because the constitutional burden remains upon prosecutors to establish every required element beyond a reasonable doubt through admissible evidence at every stage of prosecution.
Legitimate Wound Care Should Not Be Swept into the Allegation
Skin substitutes can support wound closure and tissue growth when appropriately selected, making the prosecution an accusation about McMillan’s alleged payment and billing system rather than a general attack upon all cellular or tissue-based wound products.
Patients with chronic wounds often face infection, mobility loss, hospitalization, or amputation risks, giving clinically supported treatment genuine importance while also making expensive reimbursed products vulnerable to aggressive utilization and financial inducements within reimbursement-dependent treatment markets.
Determining claim validity may require experts to examine wound measurements, prior conservative treatment, infection status, product size, application frequency, patient response, documentation quality, program rules, and the provider’s rationale at each treatment date.
Those clinical inquiries can coexist with financial evidence, because a medically reasonable application may still present an acquisition-price issue, while an accurate price disclosure cannot independently establish that treatment satisfied applicable coverage requirements.
Compliance Lessons for Providers and Distributors
Medical practices should treat products supplied without upfront cost, invoices triggered only by reimbursement, guaranteed profit percentages, complete denied-claim protection, and distributor-managed billing as interconnected risk indicators requiring independent legal and compliance review.
Every acquisition-price representation should reconcile contracts, invoices, rebates, credits, free goods, refunds, replacement products, financing provisions, denial policies, and side communications that change the amount a provider ultimately must pay under the full commercial arrangement.
Distributors should establish pricing independently from claim outcomes, separate clinical education from financial inducements, supervise billing assistance, review representative compensation, and prohibit marketing language promising physicians assured income from government-reimbursed product use or business development activity.
Compliance teams should trace representative transactions from product purchase through shipment, application, claim submission, payer adjudication, provider collection, distributor invoice, adjustment, commission payment, corporate deposit, owner distribution, and any later valuable acquisition by company principals.
When credible concerns arise, organizations should preserve evidence, suspend questionable arrangements, obtain qualified legal and accounting advice, assess repayment or reporting obligations, and avoid transfers or communications that could create separate obstruction allegations.
Managing Public Scrutiny Lawfully
An NBC 5 Dallas-Fort Worth report on the regional crackdown described the McMillan allegations alongside luxury-property seizures, showing how vivid lifestyle imagery can dominate public understanding before complex reimbursement evidence is tested in court.
Amicus International Consulting’s crisis public-relations guidance emphasizes organized assessment, evidence preservation, accurate timelines, and disciplined communications, principles that support lawful transparency when an indictment creates immediate uncertainty among employees, patients, lenders, vendors, and business partners.
Its reputation-rebuilding resources also underscore the need for sustained, credible public information, requiring affected organizations to distinguish allegations from findings, seizure from forfeiture, company receipts from personal income, and news summaries from the controlling court record.
No ethical communications strategy can erase authentic proceedings, mislead investigators, pressure witnesses, conceal assets, or replace legal advocacy, but careful terminology and prompt factual corrections can reduce avoidable confusion without compromising the defense.
Companies connected with the case should designate authorized spokespeople, preserve complete records, coordinate factual statements with qualified counsel, avoid speculative accusations, and update stakeholders when verifiable procedural developments materially change the public record.
A Major Case Within the 2026 Federal Crackdown
The Justice Department announced McMillan’s prosecution during the 2026 National Health Care Fraud Takedown, which authorities said charged 455 defendants across fifty-six federal districts in alleged schemes collectively involving more than $6.5 billion in false claims.
Northern District of Texas prosecutors announced seven cases involving thirteen defendants and more than $365 million in collective alleged billing, with McMillan’s approximately $268 million matter representing the largest individually disclosed local figure.
The coordinated announcement increases visibility but does not combine the regional defendants into one conspiracy, meaning allegations involving laboratories, hospice services, test kits, neurological testing, equipment, or other providers cannot establish McMillan’s guilt.
Federal officials credited investigators from the Federal Bureau of Investigation, the health department inspector general, defense investigators, and the veterans department inspector general with developing the allegations presented against McMillan across several jurisdictions.
What Happens Next
The prosecution will advance through discovery, motions, expert analysis, possible plea negotiations, asset litigation, and potentially trial, with timing influenced by the volume of claims, provider records, financial evidence, and electronically stored communications.
Future filings may identify cooperating witnesses, clarify disputed billing guidance, narrow the claim universe, disclose additional seizure information, resolve evidence challenges, or reveal how prosecutors intend to prove knowledge across corporate and provider relationships.
Courts may separately determine whether restrained property remains available for forfeiture, returns to McMillan, or belongs partly or entirely to lenders, co-owners, businesses, spouses, or other qualifying third parties with legitimate interests following separate evidentiary proceedings.
Until McMillan enters a valid guilty plea or prosecutors prove every required element beyond a reasonable doubt, all healthcare-fraud, kickback, transactional-money-laundering, seizure, and forfeiture allegations remain unresolved under the continuing presumption of innocence.
